In 2024, Independence Health Group, the for-profit parent company of the nonprofit Philadelphia-based health insurance company Independence Blue Cross, reported a net loss of $239 million, despite generating $32 billion of revenue, citing a sharp increase in medical and pharmacy costs. One driver behind these losses is the rapid growth of weight-loss medications, including glucagon-like peptide-1 receptor agonists, known as GLP-1s, such as Ozempic
Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers
PET imaging in the assessment of normal and impaired cognitive function
Patients should always follow the prescription label and instructions from their licensed healthcare provider
The accelerated approval for Eisai and Biogens Leqembi (lecanemab) was converted to a full approval based on results from the confirmatory Clarity-AD trial, which the FDA said in its statement verified the drugs benefit
It gives you results that no medicine can give you
